Veronica Muskheli

TL;DR: This work generated highly purified human cardiomyocytes using a readily scalable system for directed differentiation that relies on activin A and BMP4, and identified a cocktail of pro-survival factors that limitsCardiomyocyte death after transplantation.

TL;DR: It is shown that hESC-CMs can be produced at a clinical scale (more than one billion cells per batch) and cryopreserved with good viability and can remuscularize substantial amounts of the infarcted monkey heart.

TL;DR: Injured hearts with hESC-CM grafts show improved mechanical function and a significantly reduced incidence of both spontaneous and induced ventricular tachycardia, providing support for the continued development of h ESC-based cardiac therapies for both mechanical and electrical repair.

TL;DR: Undifferentiated ES cells were not guided toward a cardiomyocyte fate in either normal or infarcted hearts’ and there was no evidence for allogeneic immune tolerance of ES cell derivatives.

TL;DR: The results indicate that both mechanical load and vascular cell coculture control cardiomyocyte proliferation, and that mechanical load further controls the hypertrophy and architecture of engineered human myocardium.